Association of Plasma Pentraxin-3 Level with Lipid Levels and Cardiovascular Risk Factors in People with No History of Lipid-Lowering Medication: the Dong-gu Study

Overview

Journal J Atheroscler Thromb

Date 2019 Jan 25

PMID 30674758

Citations 6

Authors

Ran Lee

Hye-Ran Ahn

Min-Ho Shin

Hee-Nam Kim

Young-Hoon Lee

Seong-Woo Choi

Sun-Seog Kweon

Affiliations

Soon will be listed here.

Abstract

Aim: To elucidate the role of pentraxin-3 (PTX3) in atherosclerosis, we evaluated lipid and cardiovascular risk profiles according to the plasma PTX3 levels in subjects from the general population.

Methods: A sub-cohort of 2,000 subjects was randomly sampled from a Korean community-based cohort study. After excluding those with a medication history for dyslipidemia, 1,747 subjects (902 men and 845 women) were included in the final analyses. Linear and logistic regressions with adjustment for appropriate variables were performed.

Results: The PTX3 level was positively associated with the high-density lipoprotein cholesterol (HDL-C) level and negatively associated with the log-transformed triglyceride (TG) level, total cholesterol/HDL-C ratio, and low-density lipoprotein cholesterol (LDL-C)/HDL-C ratio (p＜0.05). Subjects with the highest PTX3 levels (≥ 1.17 ng/dl) exhibited a lower risk of metabolic syndrome (odds ratio [OR] 0.73, 95% confidence interval [CI] 0.57-0.94), overweight/obesity (OR 0.65, 95% CI 0.50-0.83), increased TG level (OR 0.66, 95% CI 0.51-0.86), and increased HDL-C level (OR 0.67, 95% CI 0.51-0.88) compared to those with the lowest PTX3 level (＜0.7 ng/dl).

Conclusion: The circulating PTX3 level was inversely associated with metabolic syndrome, overweight/obesity, and parameters of dyslipidemia, suggesting a cardioprotective role of PTX3 in atherosclerosis.

Citing Articles

Sugar-Rich Food Intake Is Negatively Associated with Plasma Pentraxin 3 Levels.

Zempo-Miyaki A, Kumagai H, Tanahashi K, Zempo H, Otsuki T, Maeda S J Obes Metab Syndr. 2023; 32(4):330-337.

PMID: 37952936 PMC: 10786211. DOI: 10.7570/jomes23027.

Effect of Statins on the Inflammatory Markers in Patients with Coronary Artery Disease.

Premnath S, Nanda S, Ray L, Arokiaraj M J Lab Physicians. 2023; 15(4):498-502.

PMID: 37780883 PMC: 10539054. DOI: 10.1055/s-0043-1768167.

[Research progress on the role of pentraxin 3 in polycystic ovary syndrome].

Wu W, Xu J Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020; 49(5):637-643.

PMID: 33210493 PMC: 8800715. DOI: 10.3785/j.issn.1008-9292.2020.08.13.

Serum pentraxin 3 as a biomarker for prognosis of acute minor stroke due to large artery atherosclerosis.

Zhang Y, Hu H, Liu C, Wu J, Zhou S, Zhao T Brain Behav. 2020; 11(1):e01956.

PMID: 33210471 PMC: 7821624. DOI: 10.1002/brb3.1956.

Bariatric surgery results in restoration of physiological plasma levels of pentraxine-3.

Tonial A, Nisihara R, Nassif P, Munhoz S, Cortina A, Gobetti J Biomed Rep. 2020; 12(2):68-72.

PMID: 31929876 PMC: 6951114. DOI: 10.3892/br.2019.1264.

References

Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F . PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000; 102(6):636-41. DOI: 10.1161/01.cir.102.6.636. View

Pearson T, Mensah G, Alexander R, Anderson J, Cannon 3rd R, Criqui M . Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107(3):499-511. DOI: 10.1161/01.cir.0000052939.59093.45. View

Nauta A, Bottazzi B, Mantovani A, Salvatori G, Kishore U, Schwaeble W . Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol. 2003; 33(2):465-73. DOI: 10.1002/immu.200310022. View

Levey A, Coresh J, Balk E, Kausz A, Levin A, Steffes M . National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003; 139(2):137-47. DOI: 10.7326/0003-4819-139-2-200307150-00013. View

Grundy S, Brewer Jr H, Cleeman J, Smith Jr S, Lenfant C . Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol. 2004; 24(2):e13-8. DOI: 10.1161/01.ATV.0000111245.75752.C6. View

Klouche M, Peri G, Knabbe C, Eckstein H, Schmid F, Schmitz G . Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis. 2004; 175(2):221-8. DOI: 10.1016/j.atherosclerosis.2004.03.020. View

Latini R, Maggioni A, Peri G, Gonzini L, Lucci D, Mocarelli P . Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004; 110(16):2349-54. DOI: 10.1161/01.CIR.0000145167.30987.2E. View

Norata G, Callegari E, Marchesi M, Chiesa G, Eriksson P, Catapano A . High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation. 2005; 111(21):2805-11. DOI: 10.1161/CIRCULATIONAHA.104.472886. View

Inoue K, Sugiyama A, Reid P, Ito Y, Miyauchi K, Mukai S . Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol. 2006; 27(1):161-7. DOI: 10.1161/01.ATV.0000252126.48375.d5. View

10.

Touboul P, Hennerici M, Meairs S, Adams H, Amarenco P, Bornstein N . Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2006; 23(1):75-80. DOI: 10.1159/000097034. View

11.

Norata G, Marchesi P, Pirillo A, Uboldi P, Chiesa G, Maina V . Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol. 2008; 28(5):925-31. DOI: 10.1161/ATVBAHA.107.160606. View

12.

Salio M, Chimenti S, de Angelis N, Molla F, Maina V, Nebuloni M . Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2008; 117(8):1055-64. DOI: 10.1161/CIRCULATIONAHA.107.749234. View

13.

Bosutti A, Malaponte G, Zanetti M, Castellino P, Heer M, Guarnieri G . Calorie restriction modulates inactivity-induced changes in the inflammatory markers C-reactive protein and pentraxin-3. J Clin Endocrinol Metab. 2008; 93(8):3226-9. DOI: 10.1210/jc.2007-1684. View

14.

Alberti L, Gilardini L, Zulian A, Micheletto G, Peri G, Doni A . Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis. 2008; 202(2):455-60. DOI: 10.1016/j.atherosclerosis.2008.05.015. View

15.

Montagnana M, Lippi G, Salvagno G, Franchini M, Targher G, Guidi G . [Role of biochemical risk factors and markers for the risk of atherosclerosis]. Recenti Prog Med. 2008; 99(4):215-22. View

16.

Zanetti M, Bosutti A, Ferreira C, Vinci P, Biolo G, Fonda M . Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. Clin Exp Med. 2009; 9(3):243-8. DOI: 10.1007/s10238-009-0039-z. View

17.

Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, Inoue K . Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med. 2009; 47(4):471-7. DOI: 10.1515/CCLM.2009.110. View

18.

Norata G, Marchesi P, Venu V, Pasqualini F, Anselmo A, Moalli F . Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation. 2009; 120(8):699-708. DOI: 10.1161/CIRCULATIONAHA.108.806547. View

19.

Ogawa T, Kawano Y, Imamura T, Kawakita K, Sagara M, Matsuo T . Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome. Obesity (Silver Spring). 2010; 18(9):1871-4. DOI: 10.1038/oby.2009.507. View

20.

Miyaki A, Maeda S, Yoshizawa M, Misono M, Sasai H, Shimojo N . Is pentraxin 3 involved in obesity-induced decrease in arterial distensibility?. J Atheroscler Thromb. 2010; 17(3):278-84. DOI: 10.5551/jat.2741. View